Cervomed announces completion of merger with eip pharma

Shares of cervomed to commence trading on nasdaq under new ticker symbol "crvo" on august 17, 2023 cervomed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with lewy bodies and other degenerative diseases of the brain cervomed has a cash runway through phase 2b clinical data which is expected during 2h 2024 boston , aug. 16, 2023 /prnewswire/ -- cervomed inc. (formerly known as diffusion pharmaceuticals inc.) (nasdaq: crvo), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with eip pharma inc. the combined company will operate under the name cervomed inc., and its shares will commence trading on a 1-for-1.5 reverse split adjusted basis on august 17, 2023, on the nasdaq capital market under the ticker symbol "crvo". cervomed's focus will be on advancing its lead drug candidate neflamapimod, an oral stress kinase inhibitor, which is currently being developed for the treatment of dementia with lewy bodies (dlb) and other degenerative diseases of the brain.
CRVO Ratings Summary
CRVO Quant Ranking